Evidence map›Paper›PMID 38447811›Full record

ArticleActa biomaterialia2024

Telodendrimer functionalized hydrogel platform for sustained antibiotics release in infection control.

Xiguang Yang, Dandan Guo, Xiaotian Ji, Changying Shi, Jennifer M Messina, Liye Suo, Juntao Luo

Open access · greenAbstract read
In one paragraph

Article in Acta biomaterialia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiguang YangDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Dandan GuoDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Xiaotian JiDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Changying ShiDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Jennifer M MessinaDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Liye SuoDepartment of Pathology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States.
Juntao LuoDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States; Department of Surgery, State University of New York Upstate Medical University, Syracuse, NY 13210, United States; Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, United States; Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, NY 13210, United States; Upstate Sepsis Interdisciplinary Research Center, State University of New York Upstate Medical University, Syracuse, NY 13210, United States. Electronic address: luoj@upstate.edu.
SUNY Upstate Medical University · US

Funding

An innovative hemoperfusion nanotrap for sepsis treatment.R01GM130941 · NIGMS · UPSTATE MEDICAL UNIVERSITY · PI LUO, JUNTAO · 2018 to 2021
$1.5M
NIGMS NIH HHS R01 GM130941
6 · The paper itself

Abstract

Wound infection commonly causes delayed healing, especially in the setting of chronic wounds. Local release of antibiotics is considered a viable approach to treat chronic wounds. We have developed a versatile telodendrimer (TD) platform for efficient loading of charged antibiotic molecules via a combination of multivalent and synergistic charge and hydrophobic interactions. The conjugation of TD in biocompatible hydrogel allows for topical application to provide sustained antibiotic release. Notably, a drug loading capacity as high as 20 % of the drug-to-resin dry weight ratio can be achieved. The payload content (PC) and release profile of the various antibiotics can be optimized by fine-tuning TD density and valency in hydrogel based on the charge and hydrophobic features of the drug, e.g., polymyxin B (PMB), gentamycin (GM), and daptomycin (Dap), for effective infection control. We have shown that hydrogel with moderately reduced TD density demonstrates a more favorable release profile than hydrogel with higher TD density. Antibiotics loaded in TD hydrogel have comparable antimicrobial potency and reduced cytotoxicity compared to the free antibiotics due to a prolonged, controlled drug release profile. In a mouse model of skin and soft tissue infection, the subcutaneous administration of PMB-loaded TD hydrogel effectively eliminated the bacterial burden. Overall, these results suggest that engineerable TD hydrogels have great potential as a topical treatment to control infection for wound healing. STATEMENT OF SIGNIFICANCE: Wound infection causes a significant delay in the wound healing process, which results in a significant financial and resource burden to the healthcare system. PEGA-telodendrimer (TD) resin hydrogel is an innovative and versatile platform that can be fine-tuned to efficiently encapsulate different antibiotics by altering charged and hydrophobic structural moieties. Additionally, this platform is advantageous as the TD density in the resin can also be fine-tuned to provide the desired antibiotic payload release profile. Sustained antibiotics release through optimization of TD density provides a prolonged therapeutic window and reduces burst release-induced cytotoxicity compared to conventional antibiotics application. Studies in a preclinical mouse model of bacteria-induced skin and soft tissue infection demonstrated promising therapeutic efficacy as evidenced by effective infection control and prolonged antibacterial efficacy of antibiotics-loaded PEGA-TD resin. In conclusion, the PEGA-TD resin platform provides a highly customizable approach for effective antibiotics release with significant potential for topical application to treat various bacterial wound infections to promote wound healing.

Indexed as

Acrylic ResinsPolyethylene GlycolsSoft Tissue InfectionsWound InfectionAnimalsAnti-Bacterial AgentsHydrogelsInfection ControlMiceAcrylic ResinsAnti-Bacterial AgentsHydrogelspoly(acryloyl-bis(aminopropyl)polyethylene glycol)Polyethylene GlycolsAntibiotics releaseHydrogelInfection controlNanocarrierTelodendrimer

Identifiers

PMID38447811
PMCPMC12887859
OpenAlexW4392468137

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.